TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28290272
Drug: SCP beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCP beverage (333 mg SCP)
Study: 21240015
Drug: Calcium 75
Normalized name: Calcium 750mg, Magnesium 465mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 75 mg · kg⁻¹ · day⁻¹ (high dose)
Study: 21240015
Drug: Calcium 45
Normalized name: Calcium 45mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium 45 mg · kg⁻¹ · day⁻¹ (low dose)
Study: 18325386
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg orally twice daily
Study: 16443339
Drug: Oral fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fat tolerance test (OFTT) in menopausal women with MetS
Study: 7534055
Drug: Heparin-coated cardiopulmonary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated cardiopulmonary bypass
Study: 8905004
Drug: Formoterol inhaled
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol inhaled via dry-powder (DP) capsule inhaler
Study: 8905004
Drug: Formoterol inhaled
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol inhaled via pressurized metered-dose inhaler (pMDI)
Study: 1910651
Drug: Weekly (intensive)
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly (intensive) neurodevelopmental therapy
Study: 1910651
Drug: Monthly (basic)
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly (basic) neurodevelopmental therapy
Study: 7082780
Drug: New enteric-coated
Normalized name: EC-0652
DrugBank: EC-0652 (DB15340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New enteric-coated phenylbutazone (100 mg and 200 mg)
Study: 31861714
Drug: Lumbar lordotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar lordotic curve-controlled traction (L-LCCT)
Study: 28615931
Drug: Indacaterol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indacaterol 150 µg
Study: 9444800
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg prolonged-release capsule per day
Study: 9444800
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg enteric-coated tablet every 8 hours
Study: 8154260
Drug: Daily dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dietary supplement of a mixture consisting of vitamins (A, B1, B2, B6, E) and trace elements (calcium, iron, manganese)
Study: 8154260
Drug: Daily dietary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dietary supplement of purely vitamin C tablets
Study: 2876233
Drug: Higher-dose frusemide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-dose frusemide
Study: 29851760
Drug: 25 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg vitamin D supplements
Study: 29851760
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg vitamin D supplements
Study: 29851760
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 μg)
Study: 26099215
Drug: Riluzole 100
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole 100 mg BID for the first 24 hours followed by 50 mg BID for the following 13 days
Study: 16670161
Drug: T(4) dosage
Normalized name: 4-T-BUTYLCYCLOHEXANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: T(4) dosage adjustment aiming for serum TSH concentration less than 2 mU/liter
Study: 16670161
Drug: T(4) dosage
Normalized name: 4-T-BUTYLCYCLOHEXANOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: T(4) dosage adjustment aiming for serum TSH concentration in the upper reference range
Study: 11512311
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) as part of immunosuppression therapy
Study: 11512311
Drug: Azathioprine as
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azathioprine as part of immunosuppression therapy
Study: 8863274
Drug: 0.1% oral
Normalized name: BARIUM SO4 0.1% ORAL SUSP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% oral rinse
Study: 8863274
Drug: 0.5% oral
Normalized name: PHENOL 0.5% ORAL SPRAY TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% oral rinse
Study: 8863274
Drug: 0.01% oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% oral rinse
Study: 8863274
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg peroral ketorolac capsule
Study: 31264800
Drug: Mindfulness-Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-Based Cognitive Therapy for Children (MBCT-C)
Study: 22135277
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg p.o. q.d. for 5 days
Study: 22135277
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid 875/125 mg p.o. b.i.d. for 7 days
Study: 20568520
Drug: Muscle-derived stem
Normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscle-derived stem cells (MDSCs) therapy
Study: 20568520
Drug: Mesenchymal stem
Normalized name: Human mesenchymal stem cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesenchymal stem cells (MSCs) therapy
Study: 10799631
Drug: 3.5 mL
Normalized name: ethanol 3.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mL of undiluted albuterol nebulized for 20 inhalations every 20 minutes for a total of 3 treatments.
Study: 10799631
Drug: Albuterol diluted
Normalized name: Albuterol
DrugBank: Albuterol (DB01001)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol diluted (0.5 mL) and nebulized in normal saline (3 mL) every 20 minutes for a total of 3 treatments.
Study: 10799631
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group (undiluted albuterol)
Study: 10799631
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (diluted albuterol)
Study: 8967585
Drug: Isoflurane using
Normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoflurane using a low-flow system (fresh gas flow 2 l/min)
Study: 1640029
Drug: Combined approach
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined approach (SDD) of oropharyngeal, gastrointestinal and parenteral use of certain antibiotics
Study: 30991815
Drug: Topical ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ciprofloxacin (intraoperative plus 5 days)
Study: 29974433
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablets (FBT) 100 μg (group A)
Study: 29974433
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablets (FBT) 200 μg (group B)
Study: 29974433
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablets (FBT)
Study: 24271646
Drug: Opicapone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone (50 mg oral dose) in patients with moderate liver impairment
Study: 24271646
Drug: Opicapone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone (50 mg oral dose) in healthy subjects (control)
Study: 23022943
Drug: Miracle Fruit™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miracle Fruit™ supplement
Study: 10545689
Drug: NIHSS administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIHSS administered by neurologists
Study: 10545689
Drug: NIHSS administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIHSS administered by research nurses
Study: 10545689
Drug: NIHSS administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIHSS administered by research nurses and neurologists
Study: 376210
Drug: Clonidine three
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine three times a day with a diuretic
Study: 376210
Drug: Clonidine twice
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine twice a day with a diuretic
Study: 30739176
Drug: Ectoine lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ectoine lozenges
Study: 30739176
Drug: Hyaluronic acid
Normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hyaluronic acid lozenges
Study: 25872171
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus lornoxicam
Study: 21377715
Drug: High-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fat meal (48% fat, 49 g)
Study: 21377715
Drug: Low-fat meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fat meal (15% fat, 3 g)
Study: 21377715
Drug: High-trans fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-trans fatty acid meal (5.2 g trans fat)
Study: 21377715
Drug: Nontrans fatty
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nontrans fatty acid meal (<0.3 g trans fat)
Study: 19424036
Drug: Standard-dose cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose cyclosporine A (CsA; 150-300 ng/mL for 3 months then 100-200 ng/mL)
Study: 19424036
Drug: Low-dose cyclosporine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclosporine A (CsA; 50-100 ng/mL)
Study: 19424036
Drug: Low-dose tacrolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose tacrolimus (Tac; 3-7 ng/mL)
Study: 19424036
Drug: Low-dose sirolimus
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sirolimus (SRL; 4-8 ng/mL)
Study: 11817530
Drug: Mannitol 4
Normalized name: mannitol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 4 g/l
Study: 11817530
Drug: Mannitol 8
Normalized name: MITOMYCIN 40MG/MANNITOL 80MG/VIL INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol 8 g/l
Study: 357456
Drug: Diphenhydramine (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diphenhydramine (12.5, 25, or 50 mg)
Study: 357456
Drug: Methapyrilene (36,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methapyrilene (36, 72, or 144 mg)
Study: 7058839
Drug: Inhaled isoproterenol
Normalized name: isoproterenol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled isoproterenol alone
Study: 7058839
Drug: Isoproterenol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol plus intravenous aminophylline
Study: 7058839
Drug: Isoproterenol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isoproterenol plus a single oral dose of an elixir of theophylline
Study: 7058839
Drug: Injectable sympathomimetic
Normalized name: Sympathomimetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable sympathomimetic agent (given if treatment beyond 60 minutes was required)
Study: 25200037
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg orally 1 hour prior to induction of anesthesia
Study: 20923841
Drug: GP sequential
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP sequential testing
Study: 12044531
Drug: LAM/IFN combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM/IFN combination therapy (IFN at 5MU t.i.w. + LAM at 100mg/day)
Study: 12044531
Drug: LAM monotherapy
Normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LAM monotherapy (LAM at 100mg/day)
Study: 10527090
Drug: Isokinetic exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isokinetic exercise of the quadriceps muscle three times weekly over 8 weeks
Study: 8821072
Drug: Dopamine-agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine-agonists
Study: 2626285
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg for children younger than 12 years and 12 mg for adults every 12 hours for 3 days) in addition to standard antibacterial chemotherapy (ampicillin and chloramphenicol)
Study: 2626285
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibacterial chemotherapy alone)
Study: 1105112
Drug: Gentamicin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin (80 mg intramuscular injection at the time of anaesthetic premedication)
Study: 29319061
Drug: Xylitol gum
Normalized name: Xylitol
DrugBank: Xylitol (DB11195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylitol gum plus oral health education
Study: 19605879
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health education alone
Study: 16334720
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with Liuwei Dihuang Wan (Bolus of the Six Drugs Including Rehmanniae)
Study: 9523308
Drug: Risedronate solution
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate solution 40 mg in 30 mL of water administered directly into the stomach, second part of the duodenum, or terminal ileum over 1 minute (study A)
Study: 9523308
Drug: Risedronate solution
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate solution 40 mg in 30 mL of water administered directly into the second part of the duodenum over 1 minute and over 1 hour (study B)
Study: 8595642
Drug: Lovastatin 20
Normalized name: lovastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin 20 to 40 mg twice daily
Study: 785178
Drug: Sisomicin 75
Normalized name: sisomicin
DrugBank: Sisomicin (DB12604)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sisomicin 75 or 100mg (1.4 mg/kg) single intramuscular injection
Study: 785178
Drug: Sisomicin 50
Normalized name: sisomicin 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sisomicin 50 or 75mg (1.9 or 2.1 mg/kg) b.i.d.
Study: 11246243
Drug: Low-volume ventriculography
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-volume ventriculography (15 mL/sec for 1 sec)
Study: 11246243
Drug: Standard-volume ventriculography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-volume ventriculography (15 mL/sec for 3 sec)
Study: 27450231
Drug: Greenselect Phytosome®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greenselect Phytosome® (150 mg/dose) and piperine (15 mg/dose)
Study: 25368724
Drug: IvIg (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: IvIg (0.4 g/kg/day for 5 days)
Study: 23469601
Drug: Qiyao Xiaoke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qiyao Xiaoke Capsule (QXC), 0.4 g/pill, 6 pills each time, three times a day.
Study: 23469601
Drug: Qiyao Xiaoke
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qiyao Xiaoke Capsule (QXC)
Study: 30278110
Drug: 1 L
Normalized name: BLUE 1 LAKE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 L PEGA with PLD
Study: 30278110
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEGA
Study: 26245675
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus Trastuzumab or Lapatinib
Study: 23354353
Drug: Phospholipid-liposome solution
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phospholipid-liposome solution (Blepha Cura)
Study: 21285986
Drug: Docetaxel (D)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (D) 30 mg/m² i.v. and Epirubicin (EPI) 30 mg/m² i.v. every week (D/EPI arm)
Study: 21285986
Drug: Docetaxel (D)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (D) 70 mg/m² i.v. every 3 weeks and Prednisone (P) 5 mg twice daily (D/P arm)
Study: 12851532
Drug: Intravenous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous heparin bolus
Study: 12851532
Drug: No intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intravenous heparin bolus
Study: 8792695
Drug: Ranitidine HCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine HCI 150 mg twice daily
Study: 8792695
Drug: Ranitidine HCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine HCI 150 mg twice daily plus metoclopramide HCI 10 mg four times daily
Study: 8792695
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (ranitidine + metoclopramide)
Study: 6332178
Drug: High-dose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose infusion methotrexate (1,500 mg/m2) with leucovorin
Study: 6332178
Drug: Standard-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose methotrexate (40 mg/m2) without leucovorin
Study: 6332178
Drug: High-dose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose infusion methotrexate
Study: 6332178
Drug: Standard-dose methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose methotrexate
Study: 6332178
Drug: High-dose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose infusion methotrexate and Standard-dose methotrexate
Study: 31447547
Drug: Dextromethorphan (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (90 mg/day)
Study: 11867965
Drug: Clobetasol lotion
Normalized name: clobetasol Topical Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol lotion under hydrocolloid occlusion once weekly
Study: 11867965
Drug: Clobetasol ointment
Normalized name: clobetasol Topical Ointment
DrugBank: Clobetasol (DB11750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobetasol ointment twice daily
Study: 10573105
Drug: MPEMi combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPEMi combination (Methotrexate, Cisplatin, Etoposide, Mitomycin)
Study: 10573105
Drug: MPEpiE combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPEpiE combination (Methotrexate, Cisplatin, Epirubicin, Etoposide)
Study: 10573105
Drug: MPEpiV combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPEpiV combination (Methotrexate, Cisplatin, Epirubicin, Vincristine)
Study: 26252485
Drug: NNC0109‐0012 (0.01,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0109‐0012 (0.01, 0.05, 0.2, 0.6, 1.5, or 3.0 mg/kg single doses; 0.05, 0.2, 0.5, 1.0, or 2.0 mg/kg multiple doses every other week for 7 weeks; 2.0 mg/kg weekly doses for 7 weeks in expansion phase)
Study: 23723381
Drug: Proanthocyanidins (PA)
Normalized name: grape seed proanthocyanidins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proanthocyanidins (PA) treatment
Study: 18256415
Drug: Oral miltefosine
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral miltefosine (2.5 mg/kg/d for 28 days)
Study: 18256415
Drug: Intramuscular antimony
Normalized name: antimony
DrugBank: Antimony (DB13110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular antimony (20 mg/kg/d for 20 days)
Study: 16612915
Drug: Topical glyceryl
Normalized name: glyceryl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical glyceryl trinitrate (GTN) ointment, 0.2 percent, applied twice daily.
Study: 16612915
Drug: Oral nifedipine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nifedipine, 20 mg twice daily, retard formulation.
Study: 15322870
Drug: General recommendation
Approvals — FDA: no, EMA: no, PMDA: no
Description: General recommendation for antimicrobial therapy
Study: 9111852
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of individual out-patient and family treatment
Study: 9111852
Drug: Individual out-patient
Normalized name: Cough Out
DrugBank: Guaifenesin (DB00874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual out-patient treatment
Study: 31407484
Drug: Parecoxib sodium
Normalized name: parecoxib sodium
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Parecoxib sodium 40 mg before induction of anaesthesia, followed by 40 mg every 12 hours for 48 hours post-operation.
Study: 31407484
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered 30 minutes before induction of anaesthesia, followed by placebo every 12 hours for 48 hours post-operation.
Study: 28793834
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) with good therapist fidelity
Study: 28793834
Drug: Cognitive Processing
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Processing Therapy (CPT) with below average therapist fidelity
Study: 20140437
Drug: Tolterodine 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine 8 mg
Study: 27948084
Drug: Tropisetron plus
Normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron plus dexamethasone (5 mg IV + 10 mg oral on days 1-5)
Study: 27948084
Drug: Generic ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic ondansetron plus dexamethasone (24 mg IV + 10 mg oral on days 1-5)
Study: 9213829
Drug: Heparansulphate 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparansulphate 100 mg t.i.d.
Study: 8448092
Drug: Obturator nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obturator nerve block using 5 mL of 2.0% lidocaine followed by two or three prognostic blocks using 5 mL of 0.5% bupivacaine and 1:200,000 epinephrine, and final block with 5 mL of 6.0% phenol in glycerin